Cowen Starts Versartis (VSAR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Citi Starts Versartis (VSAR) at Buy
April 15, 2014 7:05 AM EDTCiti initiated coverage on Versartis (NASDAQ: VSAR) with a Buy rating and a price target of $60.00.
For an analyst ratings summary and ratings history on Versartis click here. For more ratings news on Versartis click here.
Shares of Versartis closed at $24.56 yesterday.
... MoreMorgan Stanley Starts Versartis (VSAR) at Overweight
April 15, 2014 7:04 AM EDTMorgan Stanley initiated coverage on Versartis (NASDAQ: VSAR) with an Overweight rating and a price target of $79.00.
For an analyst ratings summary and ratings history on Versartis click here. For more ratings news on Versartis click here.
Shares of Versartis closed at $24.56 yesterday.
... MoreUPDATE: Canaccord Genuity Starts Versartis (VSAR) at Buy
April 15, 2014 7:03 AM EDT(Updated - April 15, 2014 11:38 AM EDT)
Canaccord Genuity initiated coverage on Versartis (NASDAQ: VSAR) with a Buy rating and a price target of $36.00.
"We believe Versartis product treating growth hormone deficiency is differentiated molecularly and provides significant advantages over current treatment including... More
